Literature DB >> 7262181

Common neuroectodermal antigens on human melanoma, neuroblastoma, retinoblastoma, glioblastoma and fetal brain revealed by hybridoma antibodies raised against melanoma cells.

S K Liao, B J Clarke, P C Kwong, A Brickenden, B L Gallic, P B Dent.   

Abstract

The hybridoma system has been utilized to produce antibodies to characterize the cell surface antigens on human melanoma cells. On initial screening, two antibodies derived by the fusion of mouse myeloma cell (SP2/0-Ag14) and splenocytes from a mouse immunized with a melanoma cell line (CaCL 78-1) showed cross-reactivity with 10 melanoma cell lines and did not react with any of 4 epithelial cancer lines, or 4 normal adult fibroblast lines. However, because of reactivity with 2 neuroblastoma cell lines, additional testing with other neuroectodermal derivatives was carried out and revealed a broad cross-reactivity among melanomas, neuroblastomas, retinoblastomas and glioblastomas and against antigens shared by fetal but not adult brain. Thus, these results indicate the existence of common neuroectodermal antigens on melanoma cells. Before melanoma specificity can be claimed for, an antibody reactivity with nonmelanoma cells bearing these neuroectodermal antigen should be excluded.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7262181     DOI: 10.1002/eji.1830110603

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  Central nervous system (CNS) involvement in SLE. The diagnostic role of antibodies to neuronal antigens.

Authors:  I J Alosachie; J W Terryberry; D Mevorach; Y Chapman; M Lorber; D Torre; P Youinou; J B Peter; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Radioimmunoassay of glioma-associated antigen in cerebrospinal fluid and its usefulness for the diagnosis and monitoring of human glioma.

Authors:  J Yoshida; R Yamamoto; T Wakabayashi; M Nagata; H Seo
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

4.  Immunohistological detection of human malignant melanoma using monoclonal antibody to a melanoma-associated antigen.

Authors:  T Kageshita; M Johno; T Ono; T Arao; K Imai
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

5.  Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.

Authors:  V Feyles; W T Dixon; L K Sikora; R C McGarry; L M Jerry
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.

Authors:  I Bergman; E Arbit; M Rosenblum; S M Larson; G Heller; N K Cheung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

7.  YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients.

Authors:  Jin Zheng; Weijiang Dong; Jiangwei Zhang; Guangyue Li; Huilin Gong
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-03-01       Impact factor: 3.848

8.  Expression of neuroectodermal antigens common to melanomas, gliomas, and neuroblastomas. I. Identification by monoclonal anti-melanoma and anti-glioma antibodies.

Authors:  S Carrel; N de Tribolet; J P Mach
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

9.  Immunochemical characterization of a human high molecular weight--melanoma associated antigen identified with monoclonal antibodies.

Authors:  B S Wilson; G Ruberto; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Electron-microscopic visualization of binding of antibodies from sera of glioma patients on cultured glioma cells.

Authors:  G M Lauro; C Solheid; L Medolago-Albani; N Di Lorenzo; B Guidetti
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.